Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 2/20 | 0.47 |
| ▸ | PRCP | P42785 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5392579 | 0.82 | S1PR3 (0.59) | S1PR3PRCPNAAAEPHX1 | |
| SCHEMBL4751119 | 0.82 | S1PR3 (0.59) | S1PR3PRCPNAAAEPHX1 | |
| SCHEMBL3557711 | 0.82 | S1PR3 (0.59) | S1PR3PRCPNAAAEPHX1 | |
| SCHEMBL3553095 | 0.82 | S1PR3 (0.59) | S1PR3PRCPNAAAEPHX1 | |
| SCHEMBL3555702 | 0.82 | S1PR3 (0.59) | S1PR3PRCPNAAAEPHX1 | |
| SCHEMBL4421784 | 0.82 | S1PR3 (0.59) | S1PR3PRCPNAAAEPHX1 | |
| SCHEMBL4573866 | 0.82 | S1PR3 (0.59) | S1PR3PRCPNAAAEPHX1 | |
| SCHEMBL3553011 | 0.82 | S1PR3 (0.59) | S1PR3PRCPNAAAEPHX1 | |
| SCHEMBL29776727 | 0.82 | S1PR3 (0.59) | S1PR3PRCPNAAAEPHX1 | |
| SCHEMBL4573899 | 0.82 | S1PR3 (0.59) | S1PR3PRCPNAAAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307093-B2 | Cancer, selectivity to prostate cancer cell lines, ovarian cancer cells | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-12-11 | — | — | US | claimed |
| EP-1692121-A1 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, METHODS OF MAKING, AND USES THEREOF | University of Tennessee Research Foundation (US) | 2006-08-23 | — | — | EP | claimed |
| US-20060040998-A1 | Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-02-23 | — | — | US | claimed |
| WO-2005049591-A1 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, METHODS OF MAKING, AND USES THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-06-02 | — | — | WO | claimed |
| US-7662842-B2 | Thiazolidinone amides, thiazolidine carboxylic acid amides, and serine amides, including polyamine conjugates thereof, as selective anti-cancer agents | Ohio State Univesity Research Foundation (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090143446-A1 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, METHODS OF MAKING, AND USES THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2009-06-04 | — | — | US | disclosed |
| WO-2008128179-A1 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080255213-A1 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-10-16 | — | — | US | disclosed |
| EP-1926487-A2 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS | University of Tennessee Research Foundation (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2008036067-A2 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-03-27 | — | — | WO | disclosed |
| US-7307093-B2 | Cancer, selectivity to prostate cancer cell lines, ovarian cancer cells | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-12-11 | — | — | US | disclosed |
| US-20070155807-A1 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1723127-A2 | ANALOGS EXHIBITING INHIBITION OF CELL PROLIFERATION, METHODS OF MAKING, AND USES THEREOF | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1692121-A1 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, METHODS OF MAKING, AND USES THEREOF | University of Tennessee Research Foundation (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060040998-A1 | Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-02-23 | — | — | US | disclosed |
| US-20060014740-A1 | Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof | US GOVERNMENT - SECRETARY FOR THE ARMY | 2006-01-19 | — | — | US | disclosed |
| WO-2005086638-A2 | ANALOGS EXHIBITING INHIBITION OF CELL PROLIFERATION, METHODS OF MAKING, AND USES THEREOF | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005049591-A1 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, METHODS OF MAKING, AND USES THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143446-A1 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, METHODS OF MAKING, AND USES THEREOF | NAT1, AADAC, PPARG | S1PR3 3957/4885PRCP 2135/4885LMNA 4427/4885 |
| US-20060014740-A1 | Analogs exhibiting inhibition of cell proliferation, methods of making, and uses thereof | MKI67, MCL1, API5 | S1PR3 2345/4885PRCP 1389/4885LMNA 2940/4885 |
| US-20060040998-A1 | Thiazolidinone amides, thiazolidine carboxylic acid amides, methods of making, and uses thereof | NAT1, AADAC, PPARG | S1PR3 3957/4885PRCP 2135/4885LMNA 4427/4885 |
| US-20080255213-A1 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS | SRM, SAT1, SMS | S1PR3 679/4885PRCP 1865/4885LMNA 4179/4885 |
| US-20070155807-A1 | THIAZOLIDINONE AMIDES, THIAZOLIDINE CARBOXYLIC ACID AMIDES, AND SERINE AMIDES, INCLUDING POLYAMINE CONJUGATES THEREOF, AS SELECTIVE ANTI-CANCER AGENTS | SRM, SAT1, SMS | S1PR3 692/4885PRCP 1550/4885LMNA 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.